PRESS RELEASE published on 06/13/2025 at 07:30, 8 months 1 day ago Inside Information / Other news releases MaaT Pharma presents updated positive data for Xervyteg® in treating acute Graft-versus-Host Disease at EHA Congress, validating high efficacy observed in pivotal ARES study MaaT Pharma Acute Graft-versus-Host Disease EMA Approval Xervyteg EAP Data
PRESS RELEASE published on 06/13/2025 at 07:30, 8 months 1 day ago Informations privilégiées / Autres communiqués MaaT Pharma présente des données actualisées positives pour Xervyteg® lors du Congrès de l’EHA confirmant une forte efficacité observée dans l’étude pivotale ARES dans la maladie aiguë du greffon contre l’hôte Thérapie MaaT Pharma AGvH Xervyteg EHA
BRIEF published on 05/12/2025 at 07:35, 9 months 2 days ago Promising data for MaaT033 in ALS Microbiome Amyotrophic Lateral Sclerosis MaaT033 Safety And Tolerability Phase 1b Clinical Trial
BRIEF published on 05/12/2025 at 07:35, 9 months 2 days ago Données prometteuses pour MaaT033 dans la SLA Microbiome Sclérose Latérale Amyotrophique MaaT033 Sécurité Et Tolérabilité Essai Clinique Phase 1b
PRESS RELEASE published on 05/12/2025 at 07:30, 9 months 2 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce des données finales prometteuses pour son essai de Phase 1b évaluant MaaT033 dans la Sclérose Latérale Amyotrophique (SLA). Résultats encourageants et implications thérapeutiques importantes Microbiome Ecosystem Therapies MaaT Pharma Sclérose Latérale Amyotrophique Phase 1b Modulation Du Microbiote
BRIEF published on 04/08/2025 at 07:35, 10 months 6 days ago MaaT Pharma annonce des résultats intermédiaires positifs concernant l'innocuité du MaaT033 MaaT Pharma Essai De Phase 2b MaaT033 Allo-GCSH Sécurité DSM
BRIEF published on 04/08/2025 at 07:35, 10 months 6 days ago MaaT Pharma Announces Positive Interim Safety Results for MaaT033 Phase 2B Trial MaaT Pharma MaaT033 Allo-HSCT DSM Safety
PRESS RELEASE published on 04/08/2025 at 07:30, 10 months 6 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce résultat positif analyse intermédiaire sécurité essai clinique Phase 2b MaaT033 allo-GCSH. DSMB recommande poursuite essai sans modification Sécurité DSMB MaaT Pharma Analyse Intermédiaire Allo-GCSH
PRESS RELEASE published on 04/08/2025 at 07:30, 10 months 6 days ago Inside Information / Other news releases MaaT Pharma announces positive safety interim analysis from DSMB for Phase 2b trial evaluating MaaT033 for patients receiving Allo-HSCT, demonstrating favorable safety profile and tolerability Phase 2B Trial MaaT Pharma Safety Analysis MaaT033 Allo-HSCT
BRIEF published on 04/07/2025 at 07:35, 10 months 7 days ago MaaT Pharma : Nouvelle couverture par H.C. Wainwright & Co Cancer Cotation Euronext Microbiome Ecosystem Therapies MaaT Pharma H.C. Wainwright & Co
Published on 02/14/2026 at 01:00, 1 day 5 hours ago Orogen Royalties Announces Annual Equity Compensation Grant
Published on 02/13/2026 at 22:15, 1 day 7 hours ago Storm Completes Sale of Miminiska Project for $5.8M and Outlines Plans for 2026
Published on 02/13/2026 at 17:45, 1 day 12 hours ago Eldorado Gold Closes $2.4 Million Strategic Investment in Gemdale Gold
Published on 02/13/2026 at 14:35, 1 day 15 hours ago Datametrex Received $500,000 Purchase Order For Data Centre Solutions
Published on 02/14/2026 at 16:30, 13 hours 31 minutes ago Milano Cortina 2026 Licensed Candies Released Globally
Published on 02/14/2026 at 06:05, 23 hours 56 minutes ago The 139th Canton Fair Promotion Conferences to Be Held in Germany and Morocco, Highlighting Targeted Industry Opportunities
Published on 02/13/2026 at 19:20, 1 day 10 hours ago Retail offering successfully completed and update on Euronext Growth Oslo listing
Published on 02/13/2026 at 19:01, 1 day 11 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/13/2026 at 18:20, 1 day 11 hours ago GLOBAL TECHNOLOGY LEADERS LAUNCH TRUSTED TECH ALLIANCE
Published on 02/13/2026 at 18:05, 1 day 11 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/01/2026
Published on 02/13/2026 at 18:05, 1 day 11 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/01/2026
Published on 02/13/2026 at 17:50, 1 day 12 hours ago Number of shares and voting rights - January 2026 (In French only)
Published on 02/13/2026 at 17:50, 1 day 12 hours ago Nombre total d'actions et droits de vote - janvier 2026
